Natus Medical Inc. NTUS, +0.58% announced Monday a deal to be acquired in a deal valued at $1.2 billion by an affiliate of investment firm ArchiMed. Natus Medical’s stock was still halted for news until 7:30 a.m. Eastern. Under terms of the deal, ArchiMed will pay $33.50 in cash for each Natus Medical share outstanding, representing a 28.6% premium to Thursday’s closing price of $26.05. And the medical device company will have a 30-day go-shop period in which it can solicit proposals from third parties. The deal is expected to close in the third quarter of 2022. Separately, Natus Medical said first-quarter revenue rose 4.3% to $119.8 million, and that it incurred $3.4 million of “extraordinary” supply chain costs associated with buying semiconductors. The stock has rallied 9.8% year to date, while the S&P 500 SPX, -1.21% has lost 7.8%.
